Genentech recently won the patent for a psoriasis drug. Unfortunately, Roche’s Genentech unit prosecuted Eli Lilly for violation by claiming their psoriasis drugTalz, infringes on one of their patents.
Keytruda is now allowed only for the patients whose tumor expression levels of the biomarker PD-L1 meet a combined positive score of 10 or higher. Tecentriq can only be used where PD-L1 immune cells can cover only 5% or more of their tumor area.
Lodo Therapeutics Corporation, a drug discovery and development company focused on identifying and producing unique, bioactive natural products directly from the microbial DNA sequence information contained in soil, today announced that it has formed a strategic drug discovery collaboration with Genentech, a member of the Roche Group.
Flatiron announced a three-year agreement with Bristol-Myers Squibb (BMS) a leading pharma company from the US. BMS is planning to use Flatiron’s expertise to expand real-world evidence to develop Bristol’s experimental cancer drugs.
In the first quarter of 2018, Swiss pharmaceuticals and diagnostics player Roche group’s sales rose by 6% to CHF 13.6 billion. Sales in the pharma division increased by 7% CHF 10.7 billion mainly by strong growth in Ocrevus and Perjeta.
Roche’s balovaptan has picked up a Breakthrough Therapy Designation in the US for its potential as a treatment for people with autism spectrum disorder (ASD), potentially placing the drug on a faster path to market.
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has put forward seven new medicines for approval in the region, including new treatment options for haemophilia A, diabetes, and a very rare genetic disorder.
European regulators have issued a green light for Amgen and Allergan’s Mvasi, marking the first biosimilar of Roche’s Avastin to be approved in the region. The drug has been cleared to treat a range of indications spanning carcinoma of the colon or rectum, breast cancer; nonsquamous non-small cell lung cancer, renal cell cancer; platinum-sensitive, or platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer and cervical cancer. The companies noted that the approval came after trial data showed a high degree of similarity between Mvasi (biosimilar bevacizumab) and its reference drug, “with no clinically meaningful differences in terms of the efficacy, safety and immunogenicity between the products”. Mvasi is the first product borne out of an alliance between Amgen and Allergan to bag marketing authorisation from the European Commission, “highlighting the success of our joint commitment to developing cancer biosimilars,” noted David Nicholson, chief research and development officer at ...
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.